High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
Nadia Arang(University of California, San Francisco), J. Silvio Gutkind(National Institutes of Health), Damiano Cosimo Rigiracciolo(University of California San Diego), Craig J. Thomas(National Institutes of Health), Sydney I. Ramirez, Nevan J. Krogan(QB3), Frances A. Tosto(National Institutes of Health), Michele Ceribelli(National Institutes of Health), Farhoud Faraji(UC San Diego Health System), Simone Lubrano(University of California San Diego), Dario R. Alessi(MRC Protein Phosphorylation and Ubiquitylation Unit), Alfredo Molinolo(University of San Diego), Andrew E. Aplin(Thomas Jefferson University), Sílvia Coma(Harvard University), Yuan Zhou(Hubei University of Medicine), Jonathan A. Pachter(Verastem (United States)), Erica Stevenson(QB3), Danielle L. Swaney(Gladstone Institutes), Daehwan Kim(Chung-Ang University), Zhiyong Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Julius Bogomolovas(Heidelberg University), Jing Yang(Southwest Jiaotong University), Robert Saddawi‐Konefka(The University of Texas MD Anderson Cancer Center)
Cited by 26
Related Papers
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
|Cell|2004|3.8k
Mechanism of activation of protein kinase B by insulin and IGF‐1.
|The EMBO Journal|1996|3k